The American Association of Immunologist is hosting their annual meeting in Seattle this week, May 13-17, 2016, and AMPEL BioSolutions is there! This year AMPEL is presenting their poster entitled Meta-Analysis from Gene Expression Profiles of Lupus Affected Tissues Reveals Novel Immune Cell Contributions. For more information on IMMUNOLOGY 2016 visit https://immunology2016.zerista.com/.
George C. Tsokos, M.D., Chief of the Rheumatology Division at Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School, received the 2015 Lupus Insight Prize today for a project with great promise in improving treatment for lupus nephritis. The award was presented at FOCIS 2015, the 15th Annual Meeting of the Federation of Clinical Immunology Societies.
The Lupus Insight Prize is a collaborative initiative among the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA) and the Lupus Research Institute (LRI). The $200,000 Prize recognizes a major, novel insight and/or discovery that has the promise of changing thinking about lupus as well as a high likelihood of generating further advances in the diagnosis and treatment of the disease.
The Alliance for Lupus Research (ALR) is pleased to announce it is working with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on a clinical study to evaluate ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus (SLE, or lupus). Ustekinumab received the highest score in the biologic category of the LRxL-STAT Lupus Drug Repositioning Initiative and will be studied in a Phase 2 lupus clinical study (https://clinicaltrials.gov/ct2/show/NCT02349061?term=ustekinumab%2C+lupus&rank=1) that will begin recruiting later this year.
The ALR, in partnership with the Lupus Research Institute and Drs. Peter Lipsky and Amrie Grammer of AMPEL BioSolutions, developed the new LRxL-STAT project (www.linkedin.com/in/lrxlstat) to repurpose therapies currently approved for other indications and evaluate the effectiveness of such treatments in lupus. After scrutinizing hundreds of potential treatments using the CoLT (Combined Lupus Treatment) scoring system, the ALR and Drs. Lipsky and Grammer identified ustekinumab as a promising biologic candidate. The CoLT scoring system is an evidence-based analysis used on potential lupus therapies that incorporates scientific rationale, pre-clinical/clinical experience, drug properties and safety data. Ustekinumab is approved in the U.S. for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. The ALR established the Lupus Clinical Investigators Network (LuCIN, www.linkedin.com/in/lucinstat), which is comprised of nearly 50 academic lupus centers representing all geographic regions of the U.S., some of whom will participate in the planned clinical trial of ustekinumab, as well as in the evaluation of other potential lupus treatments in close consultation with lupus advocacy organizations.
A new trade deal could have a big impact on Virginia’s economy.
Imagine a future free of allergic reactions, lupus and cancer. Virginia scientists are already working to make this a reality: Two Virginia Bioinformatics Institute researchers have created software that predicts allergens; Charlottesville-based AMPEL Biosolutions is pioneering a potential treatment for the chronic autoimmune disease lupus; and Manassas-based MicroVAX has just begun clinical testing on a vaccine for cancer. Virginia’s biotechnology sector is literally saving lives.
It’s also improving the day-to-day lives of thousands of commonwealth citizens in the form of high-skill, well-paying work. In 2011 the Virginia biopharmaceutical sector supported nearly $8 billion in economic output and provided more than 10,700 jobs.